Koers Biodexa Pharmaceuticals Plc London S.E.
Aandelen
BDRX
GB00BNGF1L75
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 4,58 mln. 5,72 mln. 5,34 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | 21 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 57,92% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 44 | 11-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 20-06-22 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 29-10-14 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |